Vandetanib API is a pharmaceutical-grade oral multi-target tyrosine kinase inhibitor (TKI) used in targeted oncology therapies. It inhibits several receptor tyrosine kinases, including vascular endothelial growth factor receptor (VEGFR), epidermal growth factor receptor (EGFR), and RET (Rearranged during Transfection) kinase, helping suppress tumor cell proliferation and tumor angiogenesis.
Vandetanib is approved for the treatment of symptomatic or progressive medullary thyroid carcinoma (MTC) in patients with unresectable locally advanced or metastatic disease. It is also being studied for additional oncology applications involving kinase-driven malignancies.
Manufactured under WHO-GMP-certified facilities, our Vandetanib API is produced using advanced pharmaceutical manufacturing technologies to ensure exceptional purity, stability, and batch-to-batch consistency. Every batch undergoes comprehensive analytical testing and is supplied with Certificate of Analysis (CoA), Material Safety Data Sheet (MSDS), Technical Data Sheet (TDS), and complete regulatory documentation.
Vandetanib API is used in oral pharmaceutical formulations for the treatment of symptomatic or progressive medullary thyroid carcinoma (MTC).
Vandetanib inhibits VEGFR, EGFR, and RET tyrosine kinases, reducing tumor cell growth, angiogenesis, and cancer progression.
Yes. We provide CoA, MSDS, Technical Data Sheet (TDS), Product Specifications, and complete regulatory documentation with every shipment.
Yes. We supply Vandetanib API in commercial quantities with worldwide export support and customized packaging.
Get Bulk Quote via WhatsApp